| アブストラクト | AIM: The aim of this study was to look at the influence of metformin intake and duration, on urinary bladder cancer (UBC) risk, with sulfonylurea (SU) only users as control using a new user design (inception cohort). METHODS: We conducted a retrospective cohort study using data from the UK Clinical Practice Research Datalink (CPRD) including all patients with at least one prescription of oral anti-diabetic drugs (ADD) and/or insulin. The risk of UBC in different groups of ADD users (metformin alone (one), metformin in combination (two) with other ADD medication (glinides, glitazones, DPP-4-inhibitors, SUs, insulin or more than one combination), all metformin users (1 + 2) was compared with SU only users using Cox proportional hazards models. The estimates were adjusted for age, gender, smoking status, BMI and diabetes duration. RESULTS: The inception cohort included 165,398 participants of whom 132,960 were metformin users and 32,438 were SU only users. During a mean follow-up time of more than 5 years 693 patients developed UBC, 124 of the control group and 461 of the all metformin users. There was no association between metformin use and UBC risk (HR = 1.12, 95% CI 0.90, 1.40) compared with SU only users, even after adjustment for diabetes duration (HR = 1.13, 95% CI 0.90, 1.40). We found a pattern of decreasing risk of UBC with increasing duration of metformin intake, which was statistically not significant. CONCLUSION: Metformin has no influence on the risk of UBC compared with SU in type 2 diabetes patients using a new user design. |
|---|
| ジャーナル名 | British journal of clinical pharmacology |
|---|
| Pubmed追加日 | 2015/8/11 |
|---|
| 投稿者 | Goossens, Maria E; Buntinx, Frank; Zeegers, Maurice P; Driessen, J H M; De Bruin, Marie L; De Vries, Frank |
|---|
| 組織名 | Department of General Practice, KU Leuven, Leuven, Belgium.;Department of General Practice, University of Maastricht, Maastricht.;NUTRIM School of Nutrition, Metabolism and Toxicology, University of Maastricht,;Maastricht.;Utrecht Institute of Pharmaceutical Sciences, Division of Pharmacoepidemiology;and Clinical Pharmacology, Utrecht University, Utrecht.;Department of Clinical Pharmacy and Toxicology, Maastricht University Medical;Centre, Maastricht.;Research Institute CAPHRI, University of Maastricht, the Netherlands.;MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, UK. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/26256299/ |
|---|
